Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Trastuzumab, as a recombinant IgG1 kappa, is a humanized monoclonal antibody against human epidermal growth factor receptor 2. Accordingly, it is widely used in breast cancers at early and advanced stages. Dermatomyositis is a rare adverse event of trastuzumab therapy, which is not well documented y...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-07-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/517819 |
| _version_ | 1819136933319671808 |
|---|---|
| author | Minoosh Moghimi Kasra Khodadadi |
| author_facet | Minoosh Moghimi Kasra Khodadadi |
| author_sort | Minoosh Moghimi |
| collection | DOAJ |
| description | Trastuzumab, as a recombinant IgG1 kappa, is a humanized monoclonal antibody against human epidermal growth factor receptor 2. Accordingly, it is widely used in breast cancers at early and advanced stages. Dermatomyositis is a rare adverse event of trastuzumab therapy, which is not well documented yet. In this study, a patient was treated for invasive ductal carcinoma with some symptoms of rash and generalized fatigue. These symptoms started after the fifth cycle of trastuzumab, which were gradually deteriorating. This patient’s medical and family histories were unremarkable. The progression of the disease was ruled out as a possible cause of dermatomyositis, and the laboratory evaluation revealed a moderate increase in serum muscle protein (CPK). So, trastuzumab treatment was discontinued, and by passing 1 month from the start of prednisolone and hydroxychloroquine, the patient had no symptoms. |
| first_indexed | 2024-12-22T10:42:51Z |
| format | Article |
| id | doaj.art-4d3eea8b08ca4274823952d0cd6b3e94 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-22T10:42:51Z |
| publishDate | 2021-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-4d3eea8b08ca4274823952d0cd6b3e942022-12-21T18:28:59ZengKarger PublishersCase Reports in Oncology1662-65752021-07-011421134113810.1159/000517819517819Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case ReportMinoosh Moghimi0Kasra Khodadadi1Haematology-Medical Oncology, Zanjan University of Medical Sciences, Zanjan, IranInternal Medicine, Zanjan University of Medical Sciences, Zanjan, IranTrastuzumab, as a recombinant IgG1 kappa, is a humanized monoclonal antibody against human epidermal growth factor receptor 2. Accordingly, it is widely used in breast cancers at early and advanced stages. Dermatomyositis is a rare adverse event of trastuzumab therapy, which is not well documented yet. In this study, a patient was treated for invasive ductal carcinoma with some symptoms of rash and generalized fatigue. These symptoms started after the fifth cycle of trastuzumab, which were gradually deteriorating. This patient’s medical and family histories were unremarkable. The progression of the disease was ruled out as a possible cause of dermatomyositis, and the laboratory evaluation revealed a moderate increase in serum muscle protein (CPK). So, trastuzumab treatment was discontinued, and by passing 1 month from the start of prednisolone and hydroxychloroquine, the patient had no symptoms.https://www.karger.com/Article/FullText/517819breast canceranti-human epidermal growth factor receptor 2dermatomyositistrastuzumabcase report |
| spellingShingle | Minoosh Moghimi Kasra Khodadadi Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report Case Reports in Oncology breast cancer anti-human epidermal growth factor receptor 2 dermatomyositis trastuzumab case report |
| title | Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report |
| title_full | Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report |
| title_fullStr | Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report |
| title_full_unstemmed | Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report |
| title_short | Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report |
| title_sort | dermatomyositis following biosimilar trastuzumab in a breast cancer patient a case report |
| topic | breast cancer anti-human epidermal growth factor receptor 2 dermatomyositis trastuzumab case report |
| url | https://www.karger.com/Article/FullText/517819 |
| work_keys_str_mv | AT minooshmoghimi dermatomyositisfollowingbiosimilartrastuzumabinabreastcancerpatientacasereport AT kasrakhodadadi dermatomyositisfollowingbiosimilartrastuzumabinabreastcancerpatientacasereport |